INDV
NASDAQ · Pharmaceuticals
Indivior Pharmaceuticals Inc
$39.96
+1.64 (+4.28%)
Financial Highlights (FY 2026)
Revenue
1.18B
Net Income
200.03M
Gross Margin
84.1%
Profit Margin
17.0%
Rev Growth
+11.2%
D/E Ratio
5.43
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 84.1% | 84.1% | 64.4% | 64.4% |
| Operating Margin | 21.1% | 19.0% | 23.4% | 18.6% |
| Profit Margin | 17.0% | 16.1% | 17.8% | 21.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 1.18B | 1.06B | 1.33B | 1.20B |
| Gross Profit | 992.52M | 892.56M | 854.39M | 775.01M |
| Operating Income | 249.61M | 202.02M | 310.13M | 224.17M |
| Net Income | 200.03M | 161.89M | 235.99M | 261.45M |
| Gross Margin | 84.1% | 84.1% | 64.4% | 64.4% |
| Operating Margin | 21.1% | 19.0% | 23.4% | 18.6% |
| Profit Margin | 17.0% | 16.1% | 17.8% | 21.7% |
| Rev Growth | +11.2% | +11.2% | +22.2% | -7.0% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 1.97B | 1.97B | 497.34M | 438.37M |
| Total Equity | 363.03M | 363.03M | 1.81B | 1.56B |
| D/E Ratio | 5.43 | 5.43 | 0.27 | 0.28 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 249.56M | 213.21M | 342.24M | 373.82M |
| Free Cash Flow | — | — | 277.67M | 230.73M |